Protein energy malnutrition is a common problem in patients with chronic kidney disease (CKD). Scattered reports indicate that supplementation of Carnitine may improve patients’ clinical symptoms, with significant improvement in nutritional parameters. This systematic review was done to document the evidences of Carnitine effects in nutritional status of CKD patients. Peer-reviewed RCTs on Carnitine administration at any dose in CKD patients with at least four weeks of follow-up were including in the meta-analysis. Online databases (PubMed/Medline, ISI Web of Science, Embase, and Scopus) were searched to October 2017 using selected MeSH terms related to the study topic. Data was extracted independently by two reviewers using a standard form and then cross-checked. Statistical analyses were carried out with Comprehensive Meta-analysis software. Data are presented as standard mean difference (SMD) and 95% confidence interval (CI). According to the predefined criteria, a total of 14 randomized controlled clinical trials were included and screened for data extraction by two reviewers, separately. The preliminary results extracted from meta-analysis have shown that Carnitine can significantly increase the levels of albumin (SMD: -0.861; 95% CI: -1.321, -0.402), total protein (SMD: -0.418; 95% CI: -0.695, -0.141), total cholesterol (SMD: -0.350; 95% CI: -0.564, -0.135), LDL cholesterol (SMD: -0.362; 95% CI: -0.551, -0.173), transferrin (SMD: -1.465; 95% CI: -1.822, -1.108), and hemoglobin (SMD: -0.525; 95% CI: -0.732, -0.318); however there were no conclusive effects of Carnitine on body weight (SMD: -0.057; 95% CI: -0.404, 0.291) and BMI (SMD: -0.567; 95% CI: -1.548, 0.415), in pooled analyses. The results of this meta-analysis showed that there are considerable useful pieces of evidence so far about the effect of Carnitine on nutritional factors; however, there is still doubt about some evidences with this regard. It seems necessary to carry out clinical trials with stronger designs to evaluate the impact of these primary outcomes on the patients’ clinical conditions. Having this evidences, the potential role of Carnitine in improving malnutrition consequences in CKD patients would be clearly defined.

**Keywords:** Carnitine, chronic kidney disease, meta-analysis, nutritional parameters, systematic review

**INTRODUCTION**

Chronic kidney disease (CKD) is a global public health problem with an increasing incidence worldwide. It has been estimated that over 2 million people suffered from CKD in the United States in 2014. CKD is defined as the progressive loss of renal function, resulting in irreversible structural damage in nephrons.[1] Despite extensive advancements over the past years in kidney transplantation and dialysis as

**Address for correspondence:**
Dr. Shirinsadat Badri, E-mail: badri@pharm.mui.ac.ir

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

**For reprints contact:** reprints@medknow.com

**How to cite this article:** Gholipur-Shahraki T, Feizi A, Mortazavi M, Badri S. Effects of carnitine on nutritional parameters in patients with chronic kidney disease: An updated systematic review and meta-analysis. J Res Pharm Pract 2018;7:57-68.
well as novel methods of pharmacotherapy, death is still quite high among dialysis patients compared to a normal population. Malnutrition and inflammation are common issues among patients with CKD. Researches have shown that these two factors may have a substantial role in increasing the risk of death among these patients. Different biochemical factors indicate malnutrition in CKD patients,[3,4] Carnitine deficiency is believed to be one of the factors responsible for various disorders such as anemia, low blood pressure during dialysis, cardiomyopathy, and muscle weakness in dialysis patients. Maintaining the tissue or serum level of carnitine can alleviate some of these disorders.[5,6]

Carnitine, as a left-handed isomer (L-carnitine), is a relatively small and hydrophilic molecule, extensively found in milk and meat. Lysine, methionine, ascorbate, niacin, pyridoxine, and iron are among the major sources for the endogenous production of carnitine.[7] As shown in different studies, carnitine has positive clinical effects on patients’ inflammatory, nutritional, and lipid factors accompanied with a high risk of cardiovascular diseases, as well as diseases accompanied with carnitine deficiency. Moreover, carnitine can significantly improve patients’ physical performance and alleviate exercise intolerance and extreme fatigue, thereby enhancing their quality of life. Other studies have indicated that carnitine may have a role in controlling the serum levels of cholesterol and triglycerides in the normal range while improving anemia and nutritional factors.[8,9]

Nevertheless, reports on the effects of carnitine supplementation in CKD patients are different or, at the time, contradictory. Scattered reports indicate that supplementation of carnitine will improve patients’ clinical symptoms, with significant improvement in laboratory parameters, especially on lipid levels and inflammatory and nutritional parameters among hemodialysis patients. On the contrary, there are studies indicating no significant benefit with carnitine supplementation. As a result, assessing the role of carnitine in nutritional status of CKD patients by conducting a systematic review and meta-analysis of the published relevant clinical studies seems rational and promising. Hence, the goal of this paper was to document from randomized controlled trials (RCTs) the effect of carnitine on nutritional parameters in patients with CKD, by systematically reviewing the literature and performing meta-analysis.

**METHODS**

This systematic review and meta-analysis was conducted in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guideline[10,11] and was designed methodologically according to the “standards for systematic reviews.”[12-14]

The study protocol was submitted in PROSPERO (http://www.crd.york.ac.uk/PROSPERO) with the registered number CRD42015025235.

**Data source and search strategy**

Online databases (PubMed/Medline, ISI Web of Science, Embase, and Scopus) were searched from January 1970 to October 2017 using selected MeSH terms and free text terms related to the studied topic, including “L-carnitine”, “levocarnitine”, “carnitine” [using the set operator] AND “nutritional”, “albumin”, “protein”, “weight”, “body mass index (BMI)”, “BMI”, “anemia”, “hemoglobin”, “transferrin”, “cholesterol”, “low-density lipoprotein (LDL)” [using the set operator] AND “kidney disease”, “renal failure”, “end-stage renal disease (ESRD)”, “CKD”, and “dialysis”, limited to studies in humans. We also reviewed the references list of the identified publications for additional pertinent studies. No language restrictions were imposed.

**Study selection and data extraction**

The study selection was done regarding predefined PICOT (Participants/Intervention/Comparison/Outcome/Time) for this review. Peer-reviewed prospective RCTs (parallel group or crossover trials), or retrospective observational studies providing information on the effects of carnitine on nutritional parameters in patients (male/female) of any age with CKD (stages 3, 4, or 5), with at least 4 weeks of follow-up were included in the review the meta-analysis. This was performed by completing the “Defining a question and eligibility criteria” checklist,[15] describing in detail all the elements which would be explored within the review. Carnitine treatment was considered regardless of dosage for more than 4 weeks’ administration. For controlled studies, any possible comparator, including placebo or no therapy, was considered. The presence of CKD was defined according to the KDIGO (Kidney Disease: Improving Global Outcomes) guideline.[1]

The primary outcomes were changes in serum albumin (Alb), total protein, weight, BMI, hemoglobin (Hgb), transferrin, cholesterol, and LDL, as compared to control group.

Titles and abstracts were screened independently by two reviewers (clinical pharmacist and nephrologist). Case reports, reviews, editorials, and letters were excluded from qualitative analyses but screened for potential additional references. Data were extracted independently by two reviewers using a standard form designed by the researchers according to the Cochrane Collaboration,[15] and then cross-checked. Any discrepancies were confirmed by a third reviewer.
Quality and risk of bias assessment
Quality of included trials was assessed using CONSORT (Consolidated Standards of Reporting Trials) guidelines for reporting RCTs. Methodological quality was assessed independently by at least two reviewers according to the Cochrane Collaboration Handbook for systematic reviews. Reviewers independently assessed the risk of bias within each included study based on the following domains with ratings of “low risk of bias,” “high risk of bias,” and “unclear” (uncertain risk of bias); domains included: random sequence generation, allocation concealment, blinding, incomplete outcome data, and selective outcome reporting.

Data analysis
Overall standard mean difference (SMD) and 95% CI (confidence interval) was used to assess the effects of treatment on continuous variables.
Clinical heterogeneity was assessed by comparing the distribution of important participant factors (e.g., administered dose of carnitine, duration of carnitine administration, and ...), and trial factors (randomization concealment, blinding of outcome assessment, losses to follow-up, treatment type, and co-interventions). Within and between study heterogeneities were assessed using Cochran’s Q-statistics and the heterogeneity test was used to assess the null hypothesis that all studies evaluated the same effect. The effect of heterogeneity is quantified using $I^2$ which provides a measure of the degree of inconsistency between studies. As we find no evidence of heterogeneity, a fixed effects model was used; otherwise, random effects approach, meta-regression, or subgroup analysis was used in the case of statistical heterogeneity.

Statistical analyses were performed using Comprehensive Meta-analysis (Version 2.2, 2005; Biostat, Englewood, NJ, USA).

Results
The flow diagram of the selection process has been shown in Figure 1. Among the 1065 articles found in different databases, finally, 16 articles underwent quality analysis; while the meta-analysis was performed on 14 articles since the available information was insufficient for analysis in two papers. Main characteristics of these studies are summarized in Table 1.

Study characteristics
Among the 16 included articles for quality analysis, there were 15 articles with randomized controlled clinical design and one article wherein an uncontrolled prospective design had been employed. Finally, 14 articles were included in the quantitative analysis, while one of the controlled studies and also one uncontrolled study were excluded after the quality analysis.
A total of 678 individuals constituted the final population of the patients entering into the meta-analysis (from 14 included studies), ranging from 20 to 113 patients participated in each of these studies. In this regard, 315 patients were included in the case group, and 363 patients were included in the control group. All the studies had been carried out on ESRD patients under chronic hemodialysis.
From the total of 14 randomized and controlled clinical trials, in five studies Carnitine was compared with placebo, while in nine studies Carnitine was compared with the control group. In these studies, patients had received Carnitine at a dose of 750–1500 mg per dose. The duration of treatment ranged from 2 to 9 months.
**Table 1: Main characteristic of the studies reviewed**

| Study, year (reference number) | Study design | Number of patients | Intervention | Duration (months) | Outcomes |
|--------------------------------|--------------|--------------------|--------------|-------------------|----------|
| Excluded studies              |              |                    |              |                   |          |
| Kudoh et al., 2014            | Prospective uncontrolled study | 20 (male: 10; female: 10) | L-carnitine 900 mg/dose | 12 | Alb, Hgb, total cholesterol, LDL |
| Khodaverdi et al., 2009       | Randomized triple-blind clinical trial | 29 (carnitine: 14; control: 15) | L-carnitine 1000 mg/dose | 3 | Alb, Hgb, total protein, LDL |
| Included studies              |              |                    |              |                   |          |
| Vesell et al., 2001           | Randomized controlled clinical trial | 21 (carnitine: 9; control: 12); male: 25, female: 20 | L-carnitine 1000 mg/dose | 6 | Alb, total protein, total cholesterol, LDL |
| Chazot et al., 2003           | Randomized controlled clinical trial | 45 (carnitine: 23; control: 22) | L-carnitine 1000 mg/dose | 6 | Alb, body weight, BMI, total cholesterol |
| Savica et al., 2005           | Pilot study, placebo-controlled | 113 (carnitine: 48; control: 65); male: 63, female: 50 | L-carnitine 1500 mg/dose | 6 | Alb, BMI, Hgb, transferrin |
| Rathod et al., 2006           | Randomized, Single-blind, placebo-controlled clinical trial | 20 (carnitine: 10; control: 10); male: 18, female: 2 | L-carnitine 1500 mg/dose | 2 | Alb, Hgb, total cholesterol, LDL |
| Duranay et al., 2006          | Randomized controlled clinical trial | 42 (carnitine: 21; control: 21); male: 24, female: 18 | L-carnitine 1500 mg/dose | 6 | Alb, total protein, body weight, BMI, transferrin, total cholesterol, LDL |
| Sabry et al., 2010            | Randomized controlled clinical trial | 55 (carnitine: 20; control: 35); male: 35, female: 19 | L-carnitine 1500 mg/dose | 6 | Alb, total protein, total cholesterol, LDL |
| Fu et al., 2010               | Randomized, double-blind, controlled trial | 40 (carnitine: 20; control: 20); male: 22, female: 18 | L-carnitine 1000 mg/dose | 3 | Pre-Alb, Alb, LDL, total protein, total cholesterol, Hgb |
| Mortazavi et al., 2011        | Randomized, placebo-controlled, single-blind trial | 48 (carnitine: 24; control: 24) | L-carnitine 750 mg/dose | 9 | Alb, Hgb, total cholesterol, LDL |
| Suchitra et al., 2011         | Randomized, single-blind trial | 35 (carnitine: 20; control: 15); male: 22, female: 13 | L-carnitine 1000 mg/dose | 6 | Alb, total protein, total cholesterol, LDL |
| Emami Naini et al., 2012      | Controlled clinical trial | 60 (carnitine: 30; control: 30); male: 38, female: 22 | L-carnitine 750 mg/dose | 2 | Total cholesterol, LDL |
| Mortazavi et al., 2012        | Randomized, placebo-controlled, double-blind clinical trial | 36 (carnitine: 17; control: 19) | L-carnitine 750 mg/dose | 6 | Alb, Hgb, total cholesterol, LDL |
| Emami Naini et al., 2012      | Randomized, placebo-controlled, double-blind trial | 51 (carnitine: 24; control: 27); male: 26, female: 25 | L-carnitine 900 mg/dose | 4 | BMI, Hgb, LDL |
| Fukami et al., 2013           | Randomized, comparator-controlled trial | 70 (carnitine: 32; control: 38); male: 44, female: 26 | L-carnitine 900 mg/dose | 6 | Alb, Hgb, total protein, LDL |
| Ahmadi et al., 2016           | Randomized controlled clinical trial | 42 (carnitine: 17; control: 25) | L-carnitine 1000 mg/dose | 3 | Body weight, BMI |

*For all included studies, study population consisted ESRD patients on chronic hemodialysis. ESRD=End stage renal disease, Alb=Albumin, Hgb=Hemoglobin, LDL=Low-density lipoprotein (cholesterol), BMI=Body mass index

**Study quality and risk of bias**

The risk of the incidence of possible errors in RCTs is summarized in Table 2. The details of randomization method had been described in seven studies, and the details of the blinding method for the assignment of each patient to the case and control groups (allocation concealment) had been described in four studies. Hence, these studies had a low risk for the occurrence of these errors. Four studies had double-blinded design. However, other studies had not provided any information on the above-mentioned items and thereby, had a high risk of occurrence of
Table 2: Risk of the incidence of possible errors in studies reviewed*

| Study, year (reference number) | Random sequence generation | Blinding of participants and outcome assessors | Incomplete outcome data |
|--------------------------------|----------------------------|-----------------------------------------------|-------------------------|
| Vesela et al., 2001[22]        | Unclear (not stated)       | Unclear (not stated)                          | High risk (overall dropout 12.5%; 25% vs. 0% in carnitine vs. control groups) |
| Chazot et al., 2003[23]        | Unclear (not stated)       | Unclear (not stated)                          | High risk (overall dropout 15%; 17.8% vs. 12% in carnitine vs. control groups) |
| Savica et al., 2005[34]        | Unclear (not stated)       | Unclear (not stated)                          | High risk (overall dropout 23%) |
| Rathod et al., 2006[24]        | Low risk (“randomization through a table generated by a computer program”) | Low risk (patient blind) | High risk (overall dropout 12.7%; 14.3% vs. 11.11% in carnitine vs. control groups) |
| Duranay et al., 2006[25]       | Low risk (“randomization through systemic random sampling method”) | Unclear (not stated) | Low risk (no dropout) |
| Sabry et al., 2010[27]         | Unclear (not stated)       | Unable (not stated)                           | Unable (not reported) |
| Fu et al., 2010[28]            | Unclear (not stated)       | Unclear (not stated)                          | Low risk (no dropout) |
| Mortazavi et al., 2011[29]     | Low risk (“randomization through a table generated by a computer program”) | Low risk (double blind) | High risk (overall dropout 12.7%; 14.3% vs. 11.11% in carnitine vs. control groups) |
| Suchitra et al., 2011[3]       | Unclear (not stated)       | Unable (not stated)                           | Unable (not reported) |
| Emami Naini et al., 2012[10]   | Low risk (“randomization through statistical randomization methods”) | Low risk (double blind) | Low risk (no dropout) |
| Mortazavi et al., 2012[8]      | Low risk (“randomization through statistical randomization methods”) | Low risk (double blind) | High risk (overall dropout 27.7%) |
| Emami Naini et al., 2012[11]   | Low risk (“randomization through random allocation software”) | Low risk (double blind) | Low risk (overall dropout rate 5%) |
| Fukami et al., 2013[32]        | Unclear (not stated)       | Unable (not stated)                           | High risk (overall dropout 31.3%; 37.2% vs. 25.5% in carnitine vs. control groups) |
| Ahmadi et al., 2016[33]        | Low risk (“randomization through random allocation software”) | Unclear (not stated) | High risk (overall dropout 16%; 32% vs. 0% in carnitine vs. control groups) |

*For all included studies, allocation concealment and selective reporting was 'Unclear (not stated). Also, other sources of bias were 'Unknown'

these errors. Reporting bias (the possibility of selective reporting of the results) was unknown in all studies.

Outcome data

The outcome information was extracted and analyzed as follows: Alb in nine papers, weight and BMI in three articles, serum concentrations of Hgb and transferrin, respectively, in seven and two articles, the amount of total protein in five articles, total cholesterol in nine articles, and LDL in nine articles. This information is shown in Table 3.

Effects of Carnitine on primary and secondary outcomes

The results of meta-analysis conducted on outcome parameters are shown in Table 3 and Figures 2-9.

Albumin

Results of meta-analysis of the effects of Carnitine on Alb concentration are shown in Table 3 and Figure 2. Due to the F acquisition of 76.6%, the results of this test on the variable of Alb indicate that there is much heterogeneity between the studies. Therefore, random effects meta-analysis was used to reduce the impact of this heterogeneity. In addition, meta-regression was also conducted to investigate the effect of potential confounding factors as a source of heterogeneity.

In terms of the duration of carnitine administration, the prescriptions above 4 months were considered among the effective factors in the response rate to this medicine; the meta-regression results were significant only for the studies with a duration of more than 4 months (P < 0.001) and were not significant for the studies with lower than 4 months in length (P = 0.407).

Furthermore, in terms of carnitine dose, the meta-regression results were significant only for the studies at a dose of 1500 mg (P < 0.001) and were not significant for studies at a dose of 1000 (P = 0.062) or <1000 mg (P = 0.091).

Total cholesterol

The results of heterogeneity test on the variable of total cholesterol were indicative of a moderate non-significant heterogeneity among the studies (P = 0.168;
Table 3: Results of meta-analysis conducted on outcome parameters

| Primary outcome               | Articles included in meta-analysis (reference number) | Total number of patients | SMD   | 95% CI          | Test for overall effect | Effect of carnitine administration (in the case group compared to the control group) | I² test of heterogeneity | P test of heterogeneity | Effect of carnitine administration (in the case group compared to the control group) | Meta-analysis       |
|------------------------------|------------------------------------------------------|--------------------------|-------|-----------------|-------------------------|-------------------------------------------------------------------------------|--------------------------|------------------------|-------------------------------------------------------------------------------|---------------------|
| Alb                          | 9 controlled studies[2,8,22-25,28,32,34]             | 402                      | -0.861 | -1.321, -0.402  | Z = 3.672 (P < 0.001) | Significant effect (increasing trend) on the concentration of Alb              | 76.6% high heterogeneity among the studies (P < 0.001) | Fixed effects analysis       | Random effects analysis                                                   |
| Total protein                | 5 randomized controlled clinical trials[2,22,25,29,32] | 208                      | -0.418 | -0.695, -0.141  | Z = 2.954 (P = 0.003) | Significant effect (increasing trend) on the concentration of total protein   | 2.51% low heterogeneity among the studies (P = 0.392) | Fixed effects analysis       | Fixed effects analysis                                                   |
| Body weight                  | 5 randomized controlled clinical trials[23,25,33]     | 129                      | -0.057 | -0.404, -0.291  | Z = 0.319 (P = 0.750) | Non-significant effect on the patient’s weight                               | <0.01% low heterogeneity among the studies (P = 0.983) | Fixed effects analysis       | Fixed effects analysis                                                   |
| BMI                          | 3 randomized controlled clinical trials[23,33,34]     | 197                      | -0.567 | -1.548, -0.415  | Z = 1.131 (P = 0.750) | Non-significant effect on the patient’s BMI                                   | <0.01% low heterogeneity among the studies (P = 0.983) | Fixed effects analysis       | Random effects analysis                                                   |
| Total cholesterol            | 9 randomized controlled clinical trials[2,8,22-25,28-30] | 347                      | -0.350 | -0.564, -0.135  | Z = 3.199 (P = 0.001) | Significant changes (increasing trend) in total cholesterol levels            | 31.3% moderate nonsignificant heterogeneity among the studies (P = 0.168) | Fixed effects analysis       | Fixed effects analysis                                                   |
| LDL cholesterol              | 9 randomized controlled clinical trials[7,8,22,24,25,28-30] | 442                      | -0.362 | -0.551, -0.173  | Z = 3.750 (P < 0.001) | Significant changes in LDL levels                                             | <0.01% low heterogeneity among the studies (P = 0.608) | Fixed effects analysis       | Fixed effects analysis                                                   |
| Transferrin                  | 2 controlled studies[25,34]                           | 155                      | -1.465 | -1.822, -1.108  | Z = 8.042 (P < 0.001) | Significant effect (increasing trend) on the concentration of transferrin     | <0.01% low heterogeneity among the studies (P = 0.628) | Fixed effects analysis       | Fixed effects analysis                                                   |
| Hgb                          | 7 controlled studies[8,24,27,29,32,34]                | 382                      | -0.525 | -0.732, -0.318  | Z = 4.969 (P < 0.001) | Significant changes in total Hgb levels                                      | 35.6% moderate nonsignificant heterogeneity among the studies (P = 0.156) | Fixed effects analysis       | Fixed effects analysis                                                   |

SMD = Standard mean difference, CI = Confidence interval, BMI = Body mass index, LDL = Low-density lipoprotein, Alb = Albumin, Hgb = Hemoglobin
Gholipur-Shahraki, et al.: A systematic review on Carnitine effects in CKD patients

Figure 2: Forest plot of meta-analysis on albumin (9 studies)

Figure 3: Forest plot of meta-analysis on total protein (5 studies)

Figure 4: Forest plot of meta-analysis on body weight (3 studies)

Figure 5: Forest plot of meta-analysis on body mass index (3 studies)
In this regard, the L-carnitine dose, and the duration of medicine administration were considered as the confounding factors.

In terms of the duration of medicine administration, the prescriptions above 4 months were among the effective factors in the response rate to medicine ($P < 0.001$). However, in terms of medicine dose, the meta-regression results were not statistically significant for the studies with different doses.
Hemoglobin

The results of heterogeneity test on the studies evaluating the Hgb level were indicative of a moderate non-significant heterogeneity among the studies ($P = 0.156; I^2 = 35.6\%$). However, meta-regression was also carried out to investigate the effect of potential confounding factors on the rate of the changes in Hgb level concentrations in response to carnitine prescription. However, with regard to the mentioned confounding factors, the meta-regression results were not significantly different for studies with different doses and durations of Carnitine administration.

Subgroup analysis

Since a small number of articles for each variable were analyzable in this review, it was not possible to conduct a valid subgroup analysis in terms of the type and design of studies, the demographic characteristics of the populations, the rate of kidney failure at the start of the study, baseline levels of the variables, and other simultaneous treatments that had been included in the study protocol from the beginning.

Only some variables underwent subgroup analysis and meta-regression regarding the dose and duration of carnitine administration as confounding factors; so the role of these factors as a source of heterogeneity was examined among the studies. The results of the analysis have been presented for each variable.

Discussion

This review aimed to collect and analyze the pieces of evidence about the possible positive effects of carnitine administration in improving nutritional factors in CKD patients. Carnitine is an essential factor for the membrane transfer of Acyl-CoA compounds, especially for the transmission of long-chain fatty acids to the mitochondria. Carnitine has a very important role in the beta-oxidation of fatty acids which promotes the breakdown of fatty acids for the synthesis of triglycerides.$^{22,23}$

In numerous clinical studies, it has been shown that the administration of carnitine in patients with kidney failure has improved various disorders, such as heart problems, intolerance, and capacity reduction in activity, muscle cramps, low blood pressure during dialysis, and anemia resistant to erythropoietin.$^{36-38}$

According to the results obtained from the systematic searches of resources, evidence in this area were limited to a uncontrolled and low-quality study,$^{35}$ as well as randomized controlled studies (comparing the effect of carnitine with placebo or standard treatment) with acceptable quality, but small sample size.$^{22,24}$ Some of these studies had not been primarily aimed to determine the clinical effect of carnitine on nutritional factors and had provided some information solely in terms of the biomarkers and index factors related to the expected outcomes in this study. Therefore, the low sample size of these studies probably does not provide sufficient power to make a meaningful conclusion about the therapeutic effects of carnitine on specified biomarkers.

In this meta-analysis, it is revealed that carnitine may have the beneficial role to improve the pattern of all studied nutritional parameters including levels of serum Alb, total protein, total cholesterol, LDL cholesterol, transferrin, and Hgb, while it has not any significant effect on body weight or BMI of the studied CKD patients.

It is important to note that all the reviewed studies had provided some information on the effect of carnitine on nutritional factors, while these parameters are, in fact, the substitute outcomes not the main malnutrition consequences. Poor control of malnutrition in CKD patients is associated with the
incidence of worse consequences in the cardiovascular system and poor quality of life, especially in dialysis patients. Therefore, the studies that explore new treatments should clarify this point whether or not the possible improvements in nutritional factors actually lead to real clinical benefits in the long run. Among the studies that were analyzed, only two studies\(^{[24,31]}\) had presented some information about the effect of treatment with carnitine on quality of life. In this regard, Rathod et al.\(^{[24]}\) had shown the positive effects of Carnitine on quality of life, but Emami Naini et al. study\(^{[31]}\) did not report any significant differences between Carnitine and placebo groups, considering patients’ quality of life. Therefore, there is contradictory evidence in this regard, and further studies are needed to be conducted. On the other hand, the target population of patients who benefits most from the administration of carnitine is still not known. The improvement of nutritional factors in CKD patients under chronic dialysis is much more difficult than the early stages of CKD due to other comorbidities and higher rates of inflammation in this population.\(^{[5,6]}\)

**Strengths and weaknesses of the study**

Before conducting this review study, its protocol had been criticized and registered in the International Database “PROSPERO.” Search of articles for including in the study was done in a systematic manner and through a comprehensive review of different databases related to the field of medicine to reduce the possibility of publication bias. In addition, a systematic and structured method was employed to extract and analyze the data in accordance with the current standards for systematic review studies. It was attempted to use two researchers (a clinical pharmacist and a nephrologist) whenever possible to go through most of the stages, including the comprehensive search of resources, information extraction, and especially the quality assessment of articles. Another noteworthy strength of this study was the fact that no restrictions were imposed in terms of the publication language of the articles, so two articles in the Persian language are also included in the study during the initial search.

The main limitation of this study was the exclusive search of electronic internet resources. Furthermore, most of the selected studies had a small sample size, and limited number of studies had provided information about the similar consequences. This limited the reliability of the findings of this meta-analysis and made us unable to do a comprehensive analysis on the subgroups for specifying the moderating factors influencing the effects of this drug. In addition, the existing heterogeneities in the patients’ population entering the studies, particularly with regard to the L-carnitine dose and the duration of intervention, as well as other patients’ concurrent medications, made it impossible to draw definitive conclusions for some variables. Thus, these findings cannot be generalized to the entire population of CKD patients.

**Conclusion**

The results of this meta-analysis showed that there are considerable useful pieces of evidence so far about the effect of carnitine on nutritional factors; however, considering the shortages previously described, there is still doubt about some evidence with this regard. Furthermore, it is noticeable that this conclusion has been extracted from some small and heterogeneous studies based on related biomarkers. Therefore, it is necessary to carry out clinical trials with stronger designs to evaluate the impact of these primary outcomes on the patients’ clinical conditions. Having this evidence, the potential role of carnitine in improving malnutrition consequences in CKD patients would be clearly defined.

**Authors’ Contribution**

Tahereh Gholipur-Shahraki contributed in searching databases and extracted data from selected articles. Awat Feizi performed meta-analysis. Mojgan Mortazavi contributed in study concept and quality analysis of selected articles. Shirinsadat Badri contributed in searching databases, data extraction and quality analysis of selected articles. All authors contributed in manuscript preparation and final editing.

**Financial support and sponsorship**

This study was done as a Pharm.D thesis project and was financially supported by Isfahan University of Medical Sciences.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1-150.
2. Suchitra MM, Ashalatha VL, Sailaja E, Rao AM, Reddy VS, Bitla AR, et al. The effect of L-carnitine supplementation on lipid parameters, inflammatory and nutritional markers in maintenance hemodialysis patients. Saudi J Kidney Dis Transpl 2011;22:1155-9.
3. Fortes Almeida A, Lima Gusmão-Sena MH, Gonzaga Oliveira LC, Santana Gomes T, Neves do Nascimento TV, Nunes Gobatto AL, et al. Inflammatory, nutritional and clinical parameters of individuals with chronic kidney disease undergoing conservative treatment. Nutr Hosp 2015;32:1376-81.
4. Mekki K, Remaoun M, Belleville J, Bouchenak M. Hemodialysis duration impairs food intake and nutritional parameters in chronic kidney disease patients. Int Urol Nephrol 2012;44:237-44.
5. Bartel LL, Hussey JL, Shrago E. Perturbation of serum carnitine levels in human adults by chronic renal disease and dialysis therapy. Am J Clin Nutr 1981;34:1314-20.
6. Debska-Slizień A, Kawecka A, Wojnarowski K, Zadrony D, Kunicka D, Król E, et al. Carnitine content in different muscles of patients receiving maintenance hemodialysis. J Ren Nutr 2007;17:275-81.
7. Borum PR. Carnitine. Annu Rev Nutr 1983;3:233-59.
8. Mortazavi M, Seirafian S, Eshaghian A, Ghassami M, Taheri S, Atapour A. Associations of oral L-carnitine with hemoglobin, lipid profile, and albumin in hemodialysis patients. JRMS 2012;(1):33-7.
9. Sloan RS, Kastan B, Rice SI, Sallee CW, Yuenger NJ, Smith B, et al. Quality of life during and between hemodialysis treatments: Role of L-carnitine supplementation. Am J Kidney Dis 1998;32:265-72.
10. Moher D, Liberati A, Tetzlaff J, Altman DG; The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2007;4:e210.
11. The Transparent Reporting of Systematic Reviews and Meta-Analysis. Available from: http://www.prisma-statement.org/statement.htm. [Last accessed on 2017 Dec 25].
12. Institute of Medicine of the National Academies. Standards for Systematic Reviews. In: Finding What Works in Health Care. Institute of Medicine of the National Academies; 2011. Available from: http://www.iom.edu/srstandards. [Last accessed on 2017 Dec 25].
13. Pai M, McCulloch M, Gorman JD, Pai N, Enanoria W, Kennedy G, et al. Systematic reviews and meta-analyses: An illustrated, step-by-step guide. Natl Med J India 2004;17:86-95.
14. The University of Edinburgh-Based Centre for Cognitive Ageing and Cognitive Epidemiology. Systematic Reviews and Meta-Analyses: A Step-by-Step Guide. Available from: http://www.cace.ed.ac.uk/research/software-resources/systematic-reviews-and-meta-analyses. [Last accessed on 2017 Dec 25].
15. O'Connor D, Green S, Higgins JP, editors. Defining the review question and developing criteria for including studies. In: Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration; 2011. Available from: http://www.cochrane-handbook.org [Last updated on 2011 Mar; Last accessed on 2017 Dec 25].
16. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. BMC Med 2010;8:18.
17. Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, et al. CONSORT for reporting randomized controlled trials in journal and conference abstracts: Explanation and elaboration. PLoS Med 2008;5:e20.
18. CONSORT 2010 Statement: The Transparent Reporting of Trials. Available from: http://www.consort-statement.org. [Last accessed on 2017 Dec 25].
19. Higgins JP, Altman DG, Sterne JA, editors. Assessing risk of bias in included studies. In: Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration; 2011. Available from: http://www.cochrane-handbook.org. [Last updated on 2011 Mar; Last accessed on 2017 Dec 25].
20. Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration; 2011. Available from: http://www.cochrane-handbook.org. [Last updated on 2011 Mar; Last accessed on 2017 Dec 25].
21. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
22. Veselá E, Racek J,Trefil L, Jankov’yich V, Pojcr M. Effect of L-carnitine supplementation in hemodialysis patients. Nephron 2001;88:218-23.
23. Chazot C, Blanc C, Hurot JM, Charra B, Jean G, Laurent G, et al. Nutritional effects of carnitine supplementation in hemodialysis patients. Clin Nephrol 2003;59:24-30.
24. Rathod R, Baig MS, Khandelwal PN, Kulkarni SG, Gade PR, Siddiqui S, et al. Results of a single blind, randomized, placebo-controlled clinical trial to study the effect of intravenous L-carnitine supplementation on health-related quality of life in Indian patients on maintenance hemodialysis. Indian J Med Sci 2006;60:143-53.
25. Duranay M, Akay H, Yılmaz FM, Senes M, Tekeli N, Yücel D, et al. Effects of L-carnitine infusions on inflammatory and nutritional markers in haemodialysis patients. Nephrol Dial Transplant 2006;21:3211-4.
26. Khodaverdi M, Zamzami E, Mousavinasab SN, Khodaverdi S, Amirmoghadami HR, Ahmadi J. Evaluation of the influence of intravenous carnitine on hemoglobin and hematocrit levels in end stage chronic renal failure patients under hemodialysis. Zanjan Univ Med Sci 2009;18:58-66.
27. Sabry AA. The role of oral L-carnitine therapy in chronic hemodialysis patients. Saudi J Kidney Dis Transpl 2010;21:454-9.
28. Fu RG, Wang L, Zhou JP, Ma F, Liu XD, Ge H, et al. The effect of levocarnitine on nutritional status and lipid metabolism during long-term maintenance hemodialysis. Acad J Xian Jiaotong Univ 2010;22:203-6.
29. Mortazavi M, Asgari S, Ghassami M, Seirafian S, Taheri S, Emami Naini A, et al. The effect of oral L-carnitine on serum albumin and inflammatory markers levels in patients under peritoneal dialysis: A randomized controlled trial. J Isfahan Med Sch 2011;29:546-54.
30. Emami Naini A, Sadeghi M, Mortazavi M, Moghadasi M, Harandi AA. Oral carnitine supplementation for dyslipidemia in chronic hemodialysis patients. Saudi J Kidney Dis Transpl 2012;23:484-8.
31. Emami Naini A, Moradi M, Mortazavi M, Amini Harandi A, Hadizadeh M, Shirani F, et al. Effects of oral L-carnitine supplementation on lipid profile, anemia, and quality of life in chronic renal disease patients under hemodialysis: A randomized, double-blinded, placebo-controlled trial. J Nutr Metab 2012;2012:510483.
32. Fukami K, Yamagishi S, Sakai K, Kaida Y, Adachi T, Ando R, et al. Potential inhibitory effects of L-carnitine supplementation on tissue advanced glycation end products in patients with hemodialysis. Rejuvenation Res 2013;16:460-6.
33. Ahmadi S, Dehghan Banadaki S, Mozaffari-Khosravi H, Vosooghi M, Dehdashti H, et al. The effect of oral L-carnitine supplementation on tissue advanced glycation end products in patients with hemodialysis. J Ren Nutr 2005;15:144-50.
34. Savica V, Santoro D, Mazlaglia G, Ciolino F, Monardo P, Calvani M, et al. L-carnitine infusions may suppress serum C-reactive protein and improve nutritional status in maintenance hemodialysis patients. J Ren Nutr 2005;15:225-30.
35. Kudoh Y, Aoyama Sh, Torri T, Chen Q, Nagahara D, Sakata H, et al. Long-term effects of oral L-carnitine supplementation on anemia in chronic hemodialysis. Cardiorenal Med 2014;4:53-59.
36. Guarnieri G. Carnitine in maintenance hemodialysis patients. J Ren Nutr 2015;25:169-75.

37. Matera M, Bellinghieri G, Costantino G, Santoro D, Calvani M, Savica V, et al. History of L-carnitine: Implications for renal disease. J Ren Nutr 2003;13:2-14.

38. Brass EP, Adler S, Sietsema KE, Hiatt WR, Orlando AM, Amato A, et al. Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients. Am J Kidney Dis 2001;37:1018-28.